Safety Study of Once-a-Day Dosing of Udenafil to Treat Erectile Dysfunction
NCT ID: NCT01901640
Last Updated: 2013-07-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
302 participants
INTERVENTIONAL
2011-11-30
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of Udenafil to Treat Erectile Dysfunction
NCT01774864
Treatment of Erectile Dysfunction - Long Term Safety and Efficacy
NCT01065012
A Study of DA-8159 in Subjects With Erectile Dysfunction
NCT00282607
Treatment of Erectile Dysfunction I
NCT01037244
A Study to Characterize the Pharmacokinetics of DA-8031 in Healthy Male Subjects
NCT01104948
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DA-8159
Udenafil(The study had one arm.)
DA-8159 (Udenafil)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DA-8159 (Udenafil)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Had hepatic or renal dysfunction
* Had significant psychiatric disorders or drug abuses
* Was currently under anticancer chemotherapy
* Had a treatments for ED using other phosphodiesterase type 5(PDE-5) inhibitors
20 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dong-A Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
S W Kim, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
the Catholic University of Korea St. Mary's Hospital
D G Moon, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Korea University Guro Hospital
J J Kim, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Korea University Anam Hospital
N C Park, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Pusan National University Hospital
S W Lee, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
J S Paick, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
T Y Ahn, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
K H Moon, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Yeungnam University Hospital
W S Chung, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Ewha Womans University Hospital
K S Min, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Inje University
J K Park, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Chonbuk National University Hospital
D Y Yang, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Kangdong Sacred Heart Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DA8159_EDDL_III
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.